Historical note and nomenclature
Article section 1 of 12.  Next

By K K Jain MD

Lacosamide, with the chemical name of (R)N-acetyl-D,L-alanine benzyl-3-methoxypropionamide, is a functionalized amino acid with novel mechanisms of action. It has been specifically developed as an antiepileptic drug for the adjunctive treatment of partial-onset seizures. It was approved in the United States by the FDA in 2008 and was also approved in the European Union in the same year. It is marketed under the trade name of “Vimpat” (UCB Pharmaceuticals). The DEA has placed lacosamide into schedule V of the Controlled Substances Act. It is also being developed for the treatment of diabetic neuropathic pain.